M
Michael R. Bishop
High Impact
Professor of Medicine
faculty
38 h-index
274 pubs
6,701 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Michael R. Bishop's research focuses on the investigation and treatment of hematologic malignancies, particularly acute lymphoblastic leukemia (ALL) and aggressive B-cell lymphomas. He has been involved in multiple clinical trials evaluating novel immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies.
Bishop has published findings from significant studies such as the ZUMA-3 trial, which assessed the efficacy of KTE-X19 CAR T-cell therapy in adult relapsed/refractory B-cell ALL. His work also includes evaluating second-line treatment options for aggressive B-cell lymphomas and the outcomes associated with commercial CAR T-cell therapies. He has investigated treatments for relapsed and refractory multiple myeloma and explored the management of complications associated with CAR-T therapy, such as cytokine release syndrome.
With a career marked by extensive publication and a high citation count, Bishop is recognized as a highly cited researcher. His collaborations within the University of Arkansas for Medical Sciences, including with Muthu Veeraputhiran and Akash Mukherjee, contribute to his ongoing work in the field of hematology and oncology. He maintains an active laboratory website detailing his research endeavors.
Metrics
- h-index: 38
- Publications: 274
- Citations: 6,701
Selected Publications
-
Polycythemia vera as a cause of systemic hypertension (2026)
Collaboration Network
Top Collaborators
Peter A. Riedell
University of Chicago (US)
18 shared publications
- Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
- Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
- Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
- Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma
- Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
Showing 5 of 18 shared publications
Andrzej Jakubowiak
University of Chicago Medical Center (US)
11 shared publications
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
- Optimization of older adults by a geriatric assessment–guided multidisciplinary clinic before CAR T-cell therapy
- Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
- Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL
- Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
Showing 5 of 11 shared publications
Justin Kline
University of Chicago (US)
11 shared publications
- Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma
- Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
- Antigen multimers: Specific, sensitive, precise, and multifunctional high-avidity CAR-staining reagents
- Optimization of older adults by a geriatric assessment–guided multidisciplinary clinic before CAR T-cell therapy
- Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL
Showing 5 of 11 shared publications
Satyajit Kosuri
University of Chicago (US)
11 shared publications
- Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
- Optimization of older adults by a geriatric assessment–guided multidisciplinary clinic before CAR T-cell therapy
- Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL
- A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
- Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah’s Witnesses
Showing 5 of 11 shared publications
Olalekan O. Oluwole
Vanderbilt University (US)
11 shared publications
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
- Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
- Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
- Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
Showing 5 of 11 shared publications
Aaron C. Logan
University of California San Francisco Medical Center (US)
8 shared publications
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
- Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
- Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Showing 5 of 8 shared publications
Matthew J. Frigault
Massachusetts General Hospital (US)
8 shared publications
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
- Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma
- Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
- Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
Showing 5 of 8 shared publications
Bijal Shah
Moffitt Cancer Center (US)
7 shared publications
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
- Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
- Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Showing 5 of 7 shared publications
Martha Arellano
Emory University (US)
7 shared publications
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
- Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
- Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Showing 5 of 7 shared publications
Noopur Raje
Harvard University (US)
7 shared publications
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
- Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
- A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
- Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
Showing 5 of 7 shared publications
Daniella Cook
Massachusetts General Hospital (US)
7 shared publications
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
- Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
- Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
- Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
Showing 5 of 7 shared publications
Jacalyn Rosenblatt
Beth Israel Deaconess Medical Center (US)
7 shared publications
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
- Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
- Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
- Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
Showing 5 of 7 shared publications
David Avigan
Harvard University (US)
7 shared publications
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
- Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
- Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
- Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
Showing 5 of 7 shared publications
Richard T. Maziarz
OHSU Knight Cancer Institute
7 shared publications
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
- Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
- Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
- Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
Showing 5 of 7 shared publications
Joseph P. McGuirk
The University of Kansas Cancer Center (US)
7 shared publications
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
- Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
- Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
- Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics
Ramya Bachu
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Immunotherapy and Immune Responses
Appalanaidu Sasapu
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Lymphoma Diagnosis and Treatment
Cancer Treatment and Pharmacology
Muthu Veeraputhiran
University of Arkansas for Medical Sciences
Acute Lymphoblastic Leukemia research
CAR-T cell therapy research
Lymphoma Diagnosis and Treatment
Munawar Hussain .
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Cesar Gentille
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Lymphoma Diagnosis and Treatment
Multiple Myeloma Research and Treatments
Jaskirat Sethi
University of Arkansas for Medical Sciences
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology